Staging — not production. cladfacts.com is live.
Menu

CLAD

Thursday, August 13, 2026

Grading Content & Exposing Bias

Outlet profile · Independent channel

Congressman Eric Burlison

1 graded report on Clad. Volume is public; the outlet's average grade, lean & social sentiment unlock with a free account.

Clad has been grading Congressman Eric Burlison coverage since Jul 2026 — 1 report so far, published as notable segments air. Its most-covered subjects on Clad: FEHB program, PBM regulation, prescription drug prices. Every report checks the segment's load-bearing claims against primary sources, then scores the coverage for factual accuracy, political lean, and how the public received it — so you can see how Congressman Eric Burlison's reporting holds up story by story, not just take its word for it.

B- Avg grade
Political Lean 65% Right-leaning

Latest reports

Video: Burlison opposes Pharmacists Fight Back Act in Oversight markup over PBM reimbursement rules
B- Grade
Political Lean 65% Right-leaning

Burlison opposes Pharmacists Fight Back Act in Oversight markup over PBM reimbursement rules

Jul 22, 2026

During a House Oversight Committee markup, Rep. Eric Burlison spoke against the Pharmacists Fight Back Act (H.R. 6610). The bill would set pharmacy reimbursement at national average drug acquisition cost plus fees, require point-of-sale rebates, mandate full rebate pass-through, and prohibit PBM steering of patients to specific pharmacies. Burlison drew on his experience on a Missouri insurance board to defend PBMs' economies of scale and performance-based pay. He referenced a 2023 Louisiana HB 529 projection of $37 million added costs and opposition from FEHB plans including Government Employee Health Association and Mail Handlers Benefit Plan.

Source: Congressman Eric Burlison